GL
GLUE.US Monte Rosa Therapeutics Inc
- Market cap
- USD 801M
- P/E
- -
- P/B
- 1.60x
- ROE
- -22.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GLUE.US undervalued?
Graham numberThe Graham number of Monte Rosa Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Monte Rosa Therapeutics Inc fundamental analysis
No fundamental analysis for Monte Rosa Therapeutics Inc yet.
Monte Rosa Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 f…
Full company profileMonte Rosa Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Monte Rosa Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.6M | 124M | 90.1M |
| Gross Profit | -72.0K | -537K | -2.13M | -8.56M | -6.22M | 67.5M | 115M | 87.4M |
| Operating Income | -7.99M | -28.0M | -72.9M | -112M | -143M | -81.1M | -54.2M | -135M |
| EBITDA | -7.67M | -27.5M | -71.8M | -101M | -129M | -62.0M | -31.4M | -104M |
| Net Income | -8.02M | -35.9M | -74.0M | -109M | -135M | -72.7M | -38.6M | -113M |
| EPS | -0.18 | -0.82 | -1.59 | -2.30 | -2.63 | -0.98 | -0.59 | -1.04 |
| Balance Sheet | ||||||||
| Total Assets | 11.1M | 49.4M | 366M | 342M | 304M | 439M | 449M | 698M |
| Total Liabilities | 23.2M | 98.1M | 18.8M | 71.0M | 125M | 216M | 216M | 202M |
| Shareholders' Equity | -12.1M | -48.7M | 348M | 271M | 179M | 223M | 233M | 496M |
| Cash & Short-term Investments | 6.00M | 41.7M | 346M | 263M | 232M | 372M | 377M | 578M |
| Total Debt | 750K | 67.8M | - | 47.0M | 46.0M | 42.7M | 39.2M | 36.3M |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.17M | -23.1M | -59.4M | -92.5M | -43.8M | 42.0M | -22.8M | -163M |
| Capital Expenditure | 1.39M | 3.39M | 9.73M | 12.9M | 19.0M | 3.99M | 4.70M | 10.9M |
| Free Cash Flow | -7.56M | -26.4M | -69.1M | -105M | -62.8M | 38.0M | -27.5M | -174M |
| Ratios | ||||||||
| ROE | - | - | -21.3% | -40.0% | -75.5% | -32.6% | -16.6% | -22.8% |
| ROA | -72.3% | -72.7% | -20.2% | -31.7% | -44.6% | -16.6% | -8.6% | -16.2% |
| Net Profit Margin | - | - | - | - | - | -96.1% | -31.2% | -125.6% |
| Debt to Equity | - | - | - | 0.17x | 0.26x | 0.19x | 0.17x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Monte Rosa Therapeutics Inc dividends
Monte Rosa Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Monte Rosa Therapeutics Inc
- Insiders 0.75%
- Institutions 99.25%
- Public & others 0.00%
- Shares outstanding 85.5M
- Free float 54.6M
Top funds holding GLUE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.56M | 3.00% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.26M | 2.64% | +2.68% | Oct 2026 |
| T. Rowe Price New Horizons | 1.98M | 2.32% | -11.03% | Sep 2026 |
| iShares Russell 2000 ETF | 1.87M | 2.18% | 0.00% | Oct 2026 |
| HBM Healthcare Investments AG Ord | 1.64M | 1.92% | -10.00% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 1.48M | 1.73% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 811K | 0.95% | +0.15% | Aug 2026 |
| T. Rowe Price Health Sciences | 749K | 0.88% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 696K | 0.82% | -0.38% | Oct 2026 |
| MEDICAL BioHealth EUR Acc | 612K | 0.72% | +0.02% | Aug 2026 |
| Vanguard Explorer Inv | 545K | 0.64% | +2.24% | Sep 2026 |
| iShares Biotechnology ETF | 462K | 0.54% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 431K | 0.50% | +1.24% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 393K | 0.46% | +0.24% | Oct 2026 |
| Avantis US Small Cap Value ETF | 382K | 0.45% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 341K | 0.40% | +2.80% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 318K | 0.37% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Mid Cap ETF | 293K | 0.34% | -1.04% | Oct 2026 |
| Dimensional US Small Cap ETF | 263K | 0.31% | 0.00% | Oct 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 258K | 0.30% | 0.00% | Oct 2026 |
Top institutions holding GLUE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 8.86M | 10.37% | +31.86% | Jun 2026 |
| NEA Management Company, LLC | 7.69M | 9.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.84M | 8.01% | +21.38% | Jun 2026 |
| TCG Crossover Management, LLC | 4.62M | 5.41% | 0.00% | Jun 2026 |
| Vestal Point Capital LP | 4.60M | 5.38% | +27.65% | Jun 2026 |
| Bvf Inc | 4.46M | 5.22% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 4.35M | 5.09% | 0.00% | Jun 2026 |
| State Street Corp | 3.73M | 4.37% | +11.25% | Jun 2026 |
| Suvretta Capital Management, LLC | 3.55M | 4.15% | -16.02% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.41M | 3.99% | +10.09% | Jun 2026 |
| Versant Venture Management LLC | 3.18M | 3.72% | 0.00% | Jun 2026 |
| BRAIDWELL LP | 2.45M | 2.87% | -23.55% | Jun 2026 |
| Geode Capital Management, LLC | 1.86M | 2.18% | +20.98% | Jun 2026 |
| American Century Companies Inc | 1.62M | 1.90% | -42.24% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.59M | 1.86% | +11.20% | Jun 2026 |
| Aisling Capital Management LP | 1.56M | 1.82% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.38M | 1.62% | +17.31% | Sep 2026 |
| Nantahala Capital Management, LLC | 1.30M | 1.53% | +100.00% | Jun 2026 |
| Bellevue Group AG | 1.19M | 1.39% | -4.80% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.16M | 1.36% | -1.35% | Jun 2026 |
Monte Rosa Therapeutics Inc company profile
- Company name
- Monte Rosa Therapeutics Inc
- Ticker
- GLUE.US
- Exchange
- USA Stocks
- Listed since
- Jun 24, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 185
- Fiscal year end
- December
- Address
- 321 Harrison Avenue, Boston, MA, United States, 02118
- Phone
- 617 949 2643
- Website
- monterosatx.com
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics Inc management
9- Dr. Markus Warmuth M.D.President, CEO & Director · born 1971
- Mr. Philip Nickson J.D., Ph.D.Chief Business & Legal Officer · born 1979
- Mr. Filip Janku M.D., Ph.D.Chief Medical Officer · born 1974
- Mr. Matthew BowenCorporate Controller & Principal Accounting Officer · born 1989
- Ms. Jennifer ChampouxChief Operating Officer · born 1972
- Mr. Magnus Walter DPHILChief Technology Officer
- Dr. John C. Castle Ph.D.Chief Data & Information Officer · born 1971
- Dr. Sharon Townson Ph.D.Chief Scientific Officer · born 1975
- Mr. Andrew FunderburkChief Investor Relations and Strategy Officer